SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Pembrolizumab Liquid Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 855 Leandro N. Alem St., 8 Floor
                                   Buenos Aires, Argentina  C1001AFB
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Immune system)

GHS label elements
Hazard pictograms :

Signal Word : Danger
Hazard Statements : H360D May damage the unborn child.
                   H373 May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:
                          P201 Obtain special instructions before use.
                          P202 Do not handle until all safety precautions have been read and understood.
                          P260 Do not breathe mist or vapors.
                          P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
SAFETY DATA SHEET

Pembrolizumab Liquid Formulation

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.
SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe vapors or spray mist.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>CMP</td>
<td>10 mg/m³</td>
<td>AR OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>TWA</td>
<td>75 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information:
A4 - Not classifiable as a human carcinogen: Agents which cause concern that they could be carcinogenic for humans but which cannot be assessed conclusively because of a lack of data. In vitro or animal studies do not provide indications of carcinogenicity which are sufficient to classify the agent into one of the other categories, lung.

Engineering measures:
- Minimize workplace exposure concentrations.
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment:
Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type

Hand protection:
- Material: Chemical-resistant gloves
Remarks

Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection

Wear the following personal protective equipment: Safety glasses

Skin and body protection

Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: suspension

Color: Colorless to pale yellow

Odor: No data available

Odor Threshold: No data available

pH: 5.5

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: No data available

Evaporation rate: No data available

Flammability (solid, gas): Not applicable

Flammability (liquids): No data available

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapor pressure: No data available

Relative vapor density: No data available

Relative density: No data available
**SAFETY DATA SHEET**

**Pembrolizumab Liquid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

- **Density**: No data available
- **Solubility(ies)**
  - Water solubility: No data available
- **Partition coefficient**: n-octanol/water
  - Autoignition temperature: No data available
- **Decomposition temperature**: No data available
- **Viscosity**
  - Viscosity, dynamic: No data available
  - Viscosity, kinematic: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.
- **Molecular weight**: No data available
- **Particle size**: No data available

### SECTION 10. STABILITY AND REACTIVITY

- **Reactivity**: Not classified as a reactivity hazard.
- **Chemical stability**: Stable under normal conditions.
- **Possibility of hazardous reactions**: Can react with strong oxidizing agents.
- **Conditions to avoid**: None known.
- **Incompatible materials**: Oxidizing agents
- **Hazardous decomposition products**: No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

- **Information on likely routes of exposure**
  - Inhalation
  - Skin contact
  - Ingestion
  - Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:**

**Sucrose:**

- **Acute oral toxicity**: LD50 (Rat): 29.700 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.
**SAFETY DATA SHEET**

**Pembrolizumab Liquid Formulation**

---

**Version** 6.2  
**Revision Date:** 09/13/2019  
**SDS Number:** 51396-00015  
**Date of last issue:** 24.04.2019  
**Date of first issue:** 23.01.2015

---

**Serious eye damage/eye irritation**  
Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**  
Not classified based on available information.

**Respiratory sensitization**  
Not classified based on available information.

**Germ cell mutagenicity**  
Not classified based on available information.

**Components:**

**Sucrose:**

Genotoxicity in vitro  
: Test Type: In vitro mammalian cell gene mutation test  
: Result: negative

**Carcinogenicity**  
Not classified based on available information.

**Reproductive toxicity**  
May damage the unborn child.

**Components:**

**Pembrolizumab:**

Reproductive toxicity - Assessment  
: May damage the unborn child., Based on data from similar materials

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**  
May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

**Components:**

**Pembrolizumab:**

Target Organs  
: Immune system  
Assessment  
: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Pembrolizumab:**

Species  
: Monkey  
NOAEL  
: 200 mg/kg  
Application Route  
: Intravenous  
Exposure time  
: 180 d  
Remarks  
: No significant adverse effects were reported
Species: Dog
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Pembrolizumab: Target Organs: Immune system
Inhalation: Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:
Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry: Not applicable

Control of precursors and essential chemicals for the preparation of drugs: Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information


Full text of other abbreviations

ACGIH: USA. ACGIH Threshold Limit Values (TLV)

AR OEL: Argentina. Occupational Exposure Limits

ACGIH / TWA: 8-hour, time-weighted average

AR OEL / CMP: TLV (Threshold Limit Value)
AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8